NZ334836A - Liquid alendronate formulations and their use in preventing bone resorption - Google Patents
Liquid alendronate formulations and their use in preventing bone resorptionInfo
- Publication number
- NZ334836A NZ334836A NZ334836A NZ33483697A NZ334836A NZ 334836 A NZ334836 A NZ 334836A NZ 334836 A NZ334836 A NZ 334836A NZ 33483697 A NZ33483697 A NZ 33483697A NZ 334836 A NZ334836 A NZ 334836A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- bone resorption
- alendronic acid
- approximately
- preventing bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2676596P | 1996-10-04 | 1996-10-04 | |
| GBGB9700541.7A GB9700541D0 (en) | 1997-01-13 | 1997-01-13 | Liquid alendronate formulation |
| US3600297P | 1997-01-22 | 1997-01-22 | |
| PCT/US1997/015740 WO1998014196A1 (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334836A true NZ334836A (en) | 2000-11-24 |
Family
ID=27268667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334836A NZ334836A (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations and their use in preventing bone resorption |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1007054A4 (xx) |
| JP (1) | JP2001501222A (xx) |
| CN (1) | CN1238691A (xx) |
| AU (1) | AU723357B2 (xx) |
| BG (1) | BG103306A (xx) |
| BR (1) | BR9712197A (xx) |
| CA (1) | CA2267370A1 (xx) |
| CZ (1) | CZ116999A3 (xx) |
| EA (1) | EA001213B1 (xx) |
| EE (1) | EE03669B1 (xx) |
| HU (1) | HUP0000125A3 (xx) |
| IL (1) | IL129127A0 (xx) |
| IS (1) | IS5012A (xx) |
| NO (1) | NO991569L (xx) |
| NZ (1) | NZ334836A (xx) |
| PL (1) | PL332496A1 (xx) |
| SK (1) | SK42999A3 (xx) |
| TR (1) | TR199900730T2 (xx) |
| WO (1) | WO1998014196A1 (xx) |
| YU (1) | YU17499A (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560490B2 (en) * | 2001-01-23 | 2009-07-14 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| JP2009508834A (ja) * | 2005-09-16 | 2009-03-05 | セラマイン リミテッド | ビスホスホネート製剤 |
| JP2010043119A (ja) * | 2009-10-16 | 2010-02-25 | Gador Sa | 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用 |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4206209A (en) * | 1978-11-02 | 1980-06-03 | Kracauer Paul | Sublingual aspirin tablet |
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
| US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
-
1997
- 1997-10-02 EP EP97945195A patent/EP1007054A4/en not_active Withdrawn
- 1997-10-02 WO PCT/US1997/015740 patent/WO1998014196A1/en not_active Application Discontinuation
- 1997-10-02 EA EA199900352A patent/EA001213B1/ru not_active IP Right Cessation
- 1997-10-02 HU HU0000125A patent/HUP0000125A3/hu unknown
- 1997-10-02 CZ CZ991169A patent/CZ116999A3/cs unknown
- 1997-10-02 TR TR1999/00730T patent/TR199900730T2/xx unknown
- 1997-10-02 JP JP10516541A patent/JP2001501222A/ja active Pending
- 1997-10-02 CA CA002267370A patent/CA2267370A1/en not_active Abandoned
- 1997-10-02 EE EEP199900113A patent/EE03669B1/xx not_active IP Right Cessation
- 1997-10-02 IL IL12912797A patent/IL129127A0/xx unknown
- 1997-10-02 CN CN97180165A patent/CN1238691A/zh active Pending
- 1997-10-02 BR BR9712197-5A patent/BR9712197A/pt unknown
- 1997-10-02 SK SK429-99A patent/SK42999A3/sk unknown
- 1997-10-02 AU AU46448/97A patent/AU723357B2/en not_active Ceased
- 1997-10-02 NZ NZ334836A patent/NZ334836A/xx unknown
- 1997-10-02 PL PL97332496A patent/PL332496A1/xx unknown
-
1999
- 1999-03-26 IS IS5012A patent/IS5012A/is unknown
- 1999-03-30 NO NO991569A patent/NO991569L/no not_active Application Discontinuation
- 1999-03-31 YU YU17499A patent/YU17499A/sr unknown
- 1999-04-02 BG BG103306A patent/BG103306A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR199900730T2 (xx) | 1999-07-21 |
| YU17499A (en) | 1999-11-22 |
| SK42999A3 (en) | 2000-01-18 |
| EA001213B1 (ru) | 2000-12-25 |
| EA199900352A1 (ru) | 1999-08-26 |
| EE03669B1 (et) | 2002-04-15 |
| CZ116999A3 (cs) | 1999-09-15 |
| IL129127A0 (en) | 2000-02-17 |
| IS5012A (is) | 1999-03-26 |
| BG103306A (en) | 2000-01-31 |
| AU723357B2 (en) | 2000-08-24 |
| EP1007054A4 (en) | 2000-07-19 |
| WO1998014196A1 (en) | 1998-04-09 |
| CA2267370A1 (en) | 1998-04-09 |
| NO991569L (no) | 1999-06-04 |
| PL332496A1 (en) | 1999-09-13 |
| BR9712197A (pt) | 1999-08-31 |
| EE9900113A (et) | 1999-10-15 |
| AU4644897A (en) | 1998-04-24 |
| EP1007054A1 (en) | 2000-06-14 |
| HUP0000125A2 (hu) | 2000-06-28 |
| NO991569D0 (no) | 1999-03-30 |
| CN1238691A (zh) | 1999-12-15 |
| JP2001501222A (ja) | 2001-01-30 |
| HUP0000125A3 (en) | 2001-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4111536B2 (ja) | 経口液体アレンドロナート組成物 | |
| EP0939624B1 (en) | Effervescent bisphosphonate formulation | |
| CA2221417A1 (en) | Anhydrous alendronate monosodium salt formulations | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| RU96123917A (ru) | Пероральные жидкие композиции, содержащие алендронат | |
| CA2288143A1 (en) | Activated protein c formulations | |
| HUP0004383A2 (hu) | Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény | |
| ES2082723B1 (es) | Formulacion farmaceutica de fluoxetina en forma dispersable. | |
| CA2386690A1 (en) | Pharmaceutical tramadol salts | |
| MX9504034A (es) | Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas. | |
| UA40663C2 (uk) | Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання | |
| CA2246501A1 (en) | Stabilised growth hormone formulation and method of preparation thereof | |
| NZ334836A (en) | Liquid alendronate formulations and their use in preventing bone resorption | |
| KR910005885B1 (ko) | 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제 | |
| ATE213940T1 (de) | Parenteral anzuwendende arzneizubereitung enthaltend amiodaron | |
| WO2000021510A3 (en) | Formulations of fexofenadine | |
| AU4787996A (en) | Calcitonin salmon analogues, their preparation, medicinal useand use as analytical agents | |
| WO1996024370B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
| CA2326339A1 (en) | Use of dexmedetomidine for icu sedation | |
| PT1175904E (pt) | Alendronato para utilização no tratamento da osteoporose | |
| CA2464151A1 (en) | Ribavirin syrup formulations | |
| GB2328872B (en) | Method for preparing pharmaceutical formulations | |
| GB2153225A (en) | Effervescent preparations containing diphosphonates | |
| MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
| EP0680760A1 (en) | Topical antipruritic composition containing a phosphonic acid diester compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |